Mechanism of action of licensed vaccine adjuvants

Vaccine

Volumn 27, Issue 25-26, 2009, Pages 3331-3334

  Tritto, Elaine ^a   Mosca, Flaviana ^a   De Gregorio, Ennio ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

Alum; Innate immunity; MF59; NLRP3 inflammasome

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ANTIGEN; CYTOKINE; IMMUNOLOGICAL ADJUVANT; INFLAMMASOME PROTEIN; INFLUENZA VACCINE; INTERLEUKIN 1BETA; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; NOD LIKE RECEPTOR PROTEIN 3; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BIOAVAILABILITY; CLINICAL TRIAL; DRUG HALF LIFE; DRUG MECHANISM; DRUG SCREENING; HUMAN; IMMUNOCOMPETENCE; IMMUNOCOMPETENT CELL; INFLUENZA; INFLUENZA VACCINATION; INJECTION SITE; INNATE IMMUNITY; LICENSING; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; CARRIER PROTEINS; DENDRITIC CELLS; HUMANS; IMMUNITY, INNATE; POLYSORBATES; SQUALENE; TOLL-LIKE RECEPTORS;

EID: 67349269509     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.01.084     Document Type: Article

References (31)

1. van Duin D., Medzhitov R., and Shaw A.C. Triggering TLR signaling in vaccination. Trends Immunol 27 January (1) (2006) 49-55
2. Krieg A.M. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 5 June (6) (2006) 471-484
3. Verdier F., Burnett R., Michelet-Habchi C., Moretto P., Fievet-Groyne F., and Sauzeat E. Aluminium assay and evaluation of the local reaction at several time points after intramuscular administration of aluminium containing vaccines in the Cynomolgus monkey. Vaccine 23 February (11) (2005) 1359-1367
4. Gupta R.K., Chang A.C., Griffin P., Rivera R., and Siber G.R. In vivo distribution of radioactivity in mice after injection of biodegradable polymer microspheres containing 14C-labeled tetanus toxoid. Vaccine 14 October (15) (1996) 1412-1416
5. Lindblad E.B. Aluminium adjuvants-in retrospect and prospect. Vaccine 22 September (27-28) (2004) 3658-3668
6. Morefield G.L., Sokolovska A., Jiang D., HogenEsch H., Robinson J.P., and Hem S.L. Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine 23 February (13) (2005) 1588-1595
7. Goto N., Kato H., Maeyama J., Shibano M., Saito T., Yamaguchi J., et al. Local tissue irritating effects and adjuvant activities of calcium phosphate and aluminium hydroxide with different physical properties. Vaccine 15 August-September (12-13) (1997) 1364-1371
8. White R.G., Coons A.H., and Connolly J.M. Studies on antibody production. III. The alum granuloma. J Exp Med 102 July (1) (1955) 73-82
9. Rimaniol A.C., Gras G., Verdier F., Capel F., Grigoriev V.B., Porcheray F., et al. Aluminum hydroxide adjuvant induces macrophage differentiation towards a specialized antigen-presenting cell type. Vaccine 22 August (23-24) (2004) 3127-3135
10. Ulanova M., Tarkowski A., Hahn-Zoric M., and Hanson L.A. The common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect Immun 69 February (2) (2001) 1151-1159
11. Seubert A., Monaci E., Pizza M., O'Hagan D.T., and Wack A. The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J Immunol 180 April (8) (2008) 5402-5412
12. Jordan M.B., Mills D.M., Kappler J., Marrack P., and Cambier J.C. Promotion of B cell immune responses via an alum-induced myeloid cell population. Science 304 June (5678) (2004) 1808-1810
13. Kool M., Soullie T., van Nimwegen M., Willart M.A., Muskens F., Jung S., et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 205 April (4) (2008) 869-882
14. Pasare C., and Medzhitov R. Control of B-cell responses by Toll-like receptors. Nature 438 November (7066) (2005) 364-368
15. Gavin A.L., Hoebe K., Duong B., Ota T., Martin C., Beutler B., et al. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science 314 December (5807) (2006) 1936-1938
16. Li H., Nookala S., and Re F. Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release. J Immunol 178 April (8) (2007) 5271-5276
17. Wack A., Baudner B.C., Hilbert A.K., Manini I., Nuti S., Tavarini S., et al. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine 26 January (4) (2008) 552-561
18. Eisenbarth S.C., Colegio O.R., O'Connor W., Sutterwala F.S., and Flavell R.A. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453 June (7198) (2008) 1122-1126
19. Franchi L., and Nunez G. The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1beta secretion but dispensable for adjuvant activity. Eur J Immunol 38 August (8) (2008) 2085-2089
20. Kool M., Soullie T., van Nimwegen M., Willart M.A., Muskens F., Jung S., et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 205 April 4 (2008) 869-882
21. Hornung V., Bauernfeind F., Halle A., Samstad E.O., Kono H., Rock K.L., et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 9 August (8) (2008) 847-856
22. Halle A., Hornung V., Petzold G.C., Stewart C.R., Monks B.G., Reinheckel T., et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol 9 August (8) (2008) 857-865
23. Ott G., Radhakrishnan R., Fang J., and Hora M. @The adjuvant MF59: a 10-year perspective. In: O'Hagan D.T. (Ed). Methods in molecular medicine, vol. 42: vaccine adjuvants: preparation methods and research protocols (2000), Humana Press Inc., Totowa, NJ 211-218
24. Schultze V., D'Agosto V., Wack A., Novicki D., Zorn J., and Hennig R. Safety of MF59 adjuvant. Vaccine 26 June (19) (2008) 3209
25. Del Giudice G., Hilbert A.K., Bugarini R., Minutello A., Popova O., Toneatto D., et al. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. Vaccine 24 April (16) (2006) 3063-3065
26. Atmar R.L., Keitel W.A., Patel S.M., Katz J.M., She D., El Sahly H., et al. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis 43 November (9) (2006) 1135-1142
27. Stephenson I., Bugarini R., Nicholson K.G., Podda A., Wood J.M., Zambon M.C., et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 191 April (8) (2005) 1210-1215
28. Dupuis M., Murphy T.J., Higgins D., Ugozzoli M., van Nest G., Ott G., et al. Dendritic cells internalize vaccine adjuvant after intramuscular injection. Cell Immunol 186 May (1) (1998) 18-27
29. Dupuis M., McDonald D.M., and Ott G. Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice. Vaccine 18 October (5-6) (1999) 434-439
30. Dupuis M., Denis-Mize K., LaBarbara A., Peters W., Charo I.F., McDonald D.M., et al. Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis. Eur J Immunol 31 October (10) (2001) 2910-2918
31. Mosca F., Tritto E., Muzzi A., Monaci E., Bagnoli F., Iavarone C., et al. Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci USA 105 July (30) (2008) 10501-10506